Rehan Verjee Biography and Net Worth

Director of Tyra Biosciences

Rehan Verjee served as President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA until March 2021. At Merck KGaA Rehan led the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business. Prior to this role, he served as Executive Vice President, Chief Marketing and Strategy Officer, leading the global franchises of oncology, neurology & immunology, and infertility, in addition to global business development, market access, strategy and portfolio management, marketing operations and the medical device and services unit. Prior to this, he led the Canadian operations as Managing Director of EMD Serono Canada. Rehan is currently a member of the board of directors of Massachusetts Biotechnology Council. He holds a master’s degree in Molecular and Cellular Biochemistry from the University of Oxford in the U.K.

What is Rehan Verjee's net worth?: The estimated net worth of Rehan Verjee is at least $21.41 thousand as of September 9th, 2026. Mr. Verjee owns 972 shares of Tyra Biosciences stock worth more than $21,413 as of September 13th. This net worth approximation does not reflect any other assets that Mr. Verjee may own. Learn More about Rehan Verjee's net worth.
How do I contact Rehan Verjee?: The corporate mailing address for Mr. Verjee and other Tyra Biosciences executives is 2656 STATE STREET, CARLSBAD CA, 92008. Tyra Biosciences can also be reached via phone at 619-728-4760 and via email at [email protected].. Learn More on Rehan Verjee's contact information.
Has Rehan Verjee been buying or selling shares of Tyra Biosciences?: During the last ninety days, Rehan Verjee has bought $20,003.76 of Tyra Biosciences stock. Most recently, on Wednesday, September 9th, Rehan Verjee bought 972 shares of Tyra Biosciences stock. The stock was acquired at an average cost of $20.58 per share, with a total value of $20,003.76. Following the completion of the transaction, the director now directly owns 972 shares of the company's stock, valued at $20,003.76. Learn More on Rehan Verjee's trading history.
Who are Tyra Biosciences' active insiders?: Tyra Biosciences' insider roster includes Daniel Bensen (COO), Alan Fuhrman (CFO), Todd Harris (CEO), Gilla Kaplan (Director), Robert More (Director), and Rehan Verjee (Director). Learn More on Tyra Biosciences' active insiders.
Are insiders buying or selling shares of Tyra Biosciences?: In the last twelve months, Tyra Biosciences insiders bought shares 1 times. They purchased a total of 972 shares worth more than $20,003.76. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 271,166 shares worth more than $5,777,623.90. The most recent insider tranaction occured on September, 9th when Director Rehan Verjee bought 972 shares worth more than $20,003.76. Insiders at Tyra Biosciences own 12.5% of the company. Learn More about insider trades at Tyra Biosciences.
Information on this page was last updated on 9/9/2026.

Rehan Verjee Insider Trading History at Tyra Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/9/2026	Buy	972	$20.58	$20,003.76	972

Rehan Verjee Buying and Selling Activity at Tyra Biosciences

Tyra Biosciences Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Today's Range

Now: $22.03

$21.86

$23.96

50 Day Range

MA: $28.39

$22.01

$33.06

2 Week Range

Now: $22.03

$11.82

$40.65

Volume

1,548,634 shs

Average Volume

873,313 shs

Market Capitalization

$1.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.73